Genedx Holdings Corp. (WGS) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Genedx Holdings Corp. (WGS) stock forecast summary
Our AI ranks Genedx Holdings Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Genedx Holdings Corp. is a small-cap company with a market capitalization of $1.94B. It ranks number 3 by market capitalization among the 10 Services-Health Services issuers in our coverage with a current forecast. Its P/B Ratio of 7.93x is the highest of the 9 peers that report one. Its Gross Margin of 69.3% is the highest of the 8 peers that report one.
A per-ticker accuracy statistic for WGS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.5%, strong sell < -1.6% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, WGS included.
Follow WGS freeWGS price chart and AI forecast
How WGS ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Genedx Holdings Corp. (WGS) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Health Services peers listed below that report each metric.
Valuation & Market
| Metric | WGS | Rank |
|---|---|---|
| Market Cap | $1.94B | 3/10 |
| P/B Ratio | 7.93x | 1/9 |
| EPS | $-3.85 | – |
| Book Value/Share | $8.19 | – |
| Revenue/Share | $15.24 | – |
| FCF/Share | $-2.54 | – |
Profitability & Margins
| Metric | WGS | Rank |
|---|---|---|
| ROE | -43.5% | 7/10 |
| ROA | -22.1% | 8/10 |
| ROIC | -22.7% | 9/11 |
| Gross Margin | 69.3% | 1/8 |
| Operating Margin | -20.3% | 9/12 |
| Net Margin | -23.4% | 7/10 |
| EBT Margin | -23.4% | 9/12 |
| Tax Rate | -0.1% | – |
Financial Health
| Metric | WGS | Rank |
|---|---|---|
| Current Ratio | 3.30x | 3/11 |
| Quick Ratio | 3.06x | – |
| D/E Ratio | 0.97x | 5/12 |
| Financial Leverage | 1.97x | 6/12 |
| Interest Coverage | -8.4x | 10/11 |
| Working Capital | $172M | 3/11 |
Cash Flow
| Metric | WGS | Rank |
|---|---|---|
| Operating Cash Flow | -$49M | 12/13 |
| Free Cash Flow | -$76M | 9/9 |
| Capital Spending | -$27M | 8/9 |
| OCF Growth YoY | -474.0% | 7/8 |
| FCF Growth YoY | -9232.3% | 6/6 |
| FCF/Sales | -16.7% | 7/9 |
| CapEx/Sales | 6.0% | 1/9 |
Operational Efficiency
| Metric | WGS | Rank |
|---|---|---|
| Asset Turnover | 0.94x | 8/11 |
| Receivables Turnover | 5.4x | 6/9 |
| Inventory Turnover | 7.8x | – |
| Fixed Assets Turnover | 8.4x | 8/10 |
| Days Sales Outstanding | 67 days | 4/9 |
| Days Inventory | 47 days | – |
| Payables Period | 14 days | – |
| Cash Conversion Cycle | 100 days | – |
Income Statement
| Metric | WGS | Rank |
|---|---|---|
| Total Revenue | $454M | 7/11 |
| Operating Income | -$92M | 11/13 |
| Net Income | -$106M | 10/11 |
| R&D Expense | $84M | – |
| SG&A Expense | $279M | 3/11 |
| Cost of Goods Sold | $139M | 4/8 |
Dividend & Shareholder Information
| Metric | WGS | Rank |
|---|---|---|
| Shares Outstanding | 30M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $246M | 51.2% of assets |
| Cash & Short-term Investments | $60M | 12.5% of assets |
| Accounts Receivable | $84M | 17.4% of assets |
| Inventory | $18M | 3.7% of assets |
| Total Liabilities | $237M | 49.3% of assets |
| Short-term Debt | $69M | 14.4% of assets |
WGS quarterly financials and insider trading
Genedx Holdings Corp. (WGS) industry peers
Companies classified under the same SEC industry code as Genedx Holdings Corp. (Services-Health Services): 13 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| WGS Genedx Holdings Corp. | ▲ | $1.94B |
| LFST Lifestance Health Group, Inc. | ▲ | $4.71B |
| PRVA Privia Health Group, Inc. | ▼ | $2.77B |
| PNTG Pennant Group, Inc. | ▶ | $1.40B |
| USPH U S Physical Therapy Inc /Nv | ▶ | $1.27B |
| INNV Innovage Holding Corp. | ▲ | $1.23B |
| OMDA Omada Health, Inc. | ▲ | $1.12B |
| SRTA Strata Critical Medical, Inc. | ▲ | $394M |
| EUDA Euda Health Holdings Ltd | ▼ | $32M |
| DCGO Docgo Inc. | ▲ | $30M |
| ATPC Agape Atp Corp | ▼ | N/A |
| PIII P3 Health Partners Inc. | ▲ | N/A |
| VSEE Vsee Health, Inc. | ▼ | N/A |
Where WGS sits on the market map
Genedx Holdings Corp. (WGS) stock news
Loading...
Genedx Holdings Corp. (WGS) stock forecast FAQ
What is the Genedx Holdings Corp. (WGS) stock forecast?
Our AI ranks Genedx Holdings Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Genedx Holdings Corp. stock predictions?
A per-ticker accuracy statistic for WGS is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Genedx Holdings Corp. forecasts updated?
Genedx Holdings Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Genedx Holdings Corp.'s industry peers?
13 issuers in our coverage, WGS included, share the SEC industry code Services-Health Services. The largest are: Lifestance Health Group, Inc. (LFST), Privia Health Group, Inc. (PRVA), Pennant Group, Inc. (PNTG), U S Physical Therapy Inc /Nv (USPH), Innovage Holding Corp. (INNV), Omada Health, Inc. (OMDA).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.